Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty

Abstract

This invention is directed to pharmaceutical combination compositions and methods containing (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N-(2-(3a(R)-benzyl-2-methyl-3-oxo-2,3, 3a, 4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1(R)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide or a pharmaceutically acceptable salt thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass, frailty and low muscle mass.

Description

Background of the invention [0001] The present invention relates to a drug combination of a selective estrogen receptor modulator (SERM) and a growth hormone secretagogue (GHS) that stimulates bone formation, increases bone mass, decreases serum lipid levels and increases muscle mass. The invention also relates to kits containing said combination and said combination for the treatment of musculoskeletal frailty, including osteoporosis, osteoporotic fractures, low bone mass, frailty, low muscle mass, in mammals, including humans. quality, etc. In particular, the present invention relates to (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8- Tetralin-2-ol or its pharmaceutically acceptable salts and 2-amino-N-(2-(3a(R)-benzyl-2-methyl-3-oxo-2,3,3a,4, 6,7-Hexahydropyrazolo[4,3-c]pyridin-5-yl)-1(R)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide or its pharmaceutical Combinations with salts, kits containing said combinations and said combinations in mammals, including...

AI Technical Summary

Problems solved by technology

[0011] 2. Decreases the rate of utilization of carbohydrates in the cells of the body;

Therefore, the product is expensive and there is a risk that diseases related to pituitary origin may be transmitted to GH users (eg Jacob-Creutzfeld disease)

Recombinant GH has recently appeared and although it no longer poses any risk of infectious disease, it is still a very expensive product and must be given by injection or nasal spray